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Essentials
• Intracranial hemorrhage (ICH) is common in patients with brain tumors.
• We compared rates of ICH with DOACs and low molecular weight heparin.
• DOACs were associated with a lower incidence of ICH in primary brain tumors.
• DOACs appear safe to administer to patients with brain tumors.
Summary. Background: Direct oral anticoagulants (DOACs) are efficacious in the treatment of cancer-associated thrombosis but are associated with an increased risk of hemorrhage compared with low-molecular-weight heparin in certain malignancies. Whether the DOACs increase the incidence of intracranial hemorrhage (ICH) in patients with brain tumors is not established. Objectives: To determine the cumulative incidence of ICH in DOACs compared with Low-molecular-weight heparin (LMWH) in patients with brain tumors and venous thromboembolism. Patients and methods: A retrospective comparative cohort study was performed. Radiographic images for all ICH events were reviewed and the primary endpoint was cumulative incidence of ICH at 12 months following initiation of anticoagulation. Results and conclusions: A total of 172 patients with brain tumors were evaluated (42 DOAC and 131 LMWH). In the primary brain tumor cohort (n = 67), the cumulative incidence of any ICH was 0% in patients receiving DOACs vs. 36.8% (95% confidence interval [CI], 22.3-51.3%) in those treated with LMWH, with a major ICH incidence of 18.2% (95% CI, 8.4-31.0). In the brain metastases cohort (n = 105), DOACs did not increase the risk of any ICH relative to enoxaparin, with an incidence of 27.8% (95% CI, 5.5-56.7%) compared with 52.9% (95% CI, 37.4-66.2%). Similarly, DOAC did not increase the incidence of major ICH in brain metastases, with a cumulative incidence 11.1% (95% CI, 0.5-40.6%) vs. 17.8% (95% CI,
Introduction
Venous thromboembolism (VTE) is a common complication of cancer. Patients with primary brain tumors and brain metastases are at particularly high risk of VTE, which has an incidence of 20-30% in this population [1, 2] . There are ongoing concerns about the safety of anticoagulation in patients with primary brain tumors and brain metastases and the risk of intracranial hemorrhage (ICH). Previously, our group and others observed that therapeutic anticoagulation with low-molecular-weight heparin does not increase the risk of ICH in patients with brain metastases but was associated with a greater than three-fold increased risk of ICH in patients with primary brain tumors compared with those not receiving therapeutic anticoagulation [3] [4] [5] [6] . Emerging data point to the efficacy of direct oral anticoagulants (DOACs) for the treatment of cancer-associated thrombosis [7, 8] . Because of their ease-of-use favored by patients and clinicians, DOACs are now commonly prescribed for the treatment of cancer-associated thrombosis [9] . Considering the influence of brain tumor diagnosis (i.e. primary vs. secondary) on the safety of anticoagulation, coupled with evidence that DOACs are associated with an increased risk of hemorrhage compared with Low-molecular-weight heparin (LMWH) in the treatment of cancer-associated thrombosis in a subset of malignancies, we sought to compare rates of ICH in patients with brain tumors treated with DOACs or LMWH.
Methods

Study design
The protocol was approved by the institutional review board at the Dana-Farber Harvard Cancer Center. Data were extracted from the electronic medical record at Beth Israel Deaconess Medical Center from 2011 to 2018. Cases were identified using the International Classification of Diseases, Ninth Revision and Tenth Revision codes for "malignant neoplasm of brain" and "malignant neoplasm of brain, metastatic." DOAC cases were identified on the basis of prescription codes for dabigatran, apixaban, rivaroxaban and/or edoxaban. LMWH cases were identified on the basis of a prescription code for an LMWH, mainly enoxaparin. The electronic medical record was then manually reviewed for each case to ensure eligibility. Inclusion criteria for all cases included: diagnosis of a solid tumor with histologically confirmed brain metastases or a World Health Organization grade III or IV glioma, including glioblastoma multiforme, anaplastic astrocytoma or anaplastic oligodendroglioma; two or more radiographic brain images to review; therapeutic anticoagulation with a DOAC or LMWH (defined as ≥ 1.5 mg kg À1 per 24 h) for the treatment of venous thromboembolism; and care received at Beth Israel Deaconess Medical Center for at least 2 months. Patients were recorded as having hypertension if hypertension was recorded in their past medical history and they required pharmacologic treatment. Patients were defined as having chronic kidney disease if they had a glomerular filtration rate < 60 mL min À1 per 1.73 m 2 .
Intracranial hemorrhage
For each case, all available radiology reports, including magnetic resonance imaging of the brain and computed tomography scan of the head from time of anticoagulant initiation were reviewed to identify instances of hemorrhage. If a radiology report indicated hemorrhage or blood products, information surrounding the event, such as indication for imaging or subsequent management, was collected from the electronic medical record. Any patient with a bleed that occurred before initiation of anticoagulation or within 4 weeks after neurosurgery was excluded from the analysis. The primary radiographic image of each instance of hemorrhage was then reviewed by a neuro-oncologist blinded to cohort allocation (DOAC vs. LMWH) to confirm the presence of hemorrhage, identify the type of hemorrhage, and calculate bleed volume using the one-half ABC technique [5] . Intracranial hemorrhages were classified as trace, measurable or major [3, 10] . Trace hemorrhages were either too small to be measured or measured < 1 mL in volume. Measurable ICHs were classified as those that measured ≥ 1 mL but < 10 mL in volume. Major ICH was defined as those that measured ≥ 10 mL in volume, required surgical intervention, or were associated with clinical symptoms, focal neurologic deficits or changes in cognitive function.
Statistical analysis
The primary endpoint of the study was major ICH within 12 months from start of anticoagulation. Variables were compared between groups using Fisher's exact test for categorical variables and the Wilcoxon rank-sum test for non-normally distributed continuous data. The cumulative incidence of bleeding was compared using the Gray test with death (without ICH) as a competing risk. Case fatality was estimated by assessing 30-day post-ICH survival using the Kaplan-Meier method. Two-sided P values less than 0.05 were considered statistically significant. Patients who were still alive were censored at the date of last contact. Patients who were discharged to hospice were considered deceased at the date of last contact.
Results
Primary brain tumors
A total of 67 patients were analyzed in the primary brain tumor cohort (Table 1) . Twenty patients received a DOAC, whereas 47 received enoxaparin. The two cohorts were well matched for age and gender but the DOAC cohort tended to have higher use of concomitant aspirin and diagnosis of hypertension. The distributions of DOACs were: rivaroxaban, n = 5; apixaban, n = 15. Two patients in the LMWH cohort switched from LMWH to a DOAC. Neither of these patients experienced ICH, and only time on LMWH was analyzed. No patients on a DOAC switched to LMWH. The cumulative incidence of any ICH at 12 months was 0% in patients receiving a DOAC compared with 36.8% (95% confidence interval, 22.3-51.3%) in those receiving enoxaparin (P = 0.007), as shown in Fig. 1 . There were no major ICH events in the DOAC group and eight and in the LMWH group (12-month cumulative incidence of 0% vs. 18.2%; 95% CI, 8.4-31.0; P = 0.049). The only ICH in the DOAC cohort occurred at 21 months and had a largest volume of 0.3 mL. The median size of the ICH in the LMWH cohort was 2 mL, with a range between trace and 62 mL. Of those who developed ICH, five patients in the LMWH cohort (28%) developed midline shift and two patients (11%) demonstrated radiographic evidence of herniation. Case fatality as estimated by post-ICH 30-day mortality was 0% in the DOAC group compared with 39% in the LMWH group. Median time from glioma diagnosis to initiation of anticoagulant treatment did not differ between the two groups (6 months for DOAC and 4 months for LMWH; Wilcoxon P = 0.61); however, the duration of anticoagulant exposure was significantly longer for DOAC-treated patients than those receiving enoxaparin (median 14 months vs. 5 months; P = 0.0004). The median number of radiographic studies reviewed were similar for DOAC (13.5) and LMWH (13, P = 0.75) groups.
Metastatic brain tumors
In the brain metastases cohort (n = 105), 21 patients received a DOAC, whereas 84 received enoxaparin ( Table 2 ). The DOAC and enoxaparin groups were well matched for tumor diagnosis (non-small-cell lung cancer 52% and 51%, respectively), including those tumor types with a high incidence of ICH (i.e. melanoma 5% and 7% and renal cell carcinoma 14% and 11%, respectively), as shown in Table 2 . Similar to the primary brain tumor group, the DOAC cohort was more likely to have additional risk factors for hemorrhage compared with the LMWH cohort, including concomitant use of aspirin (52% vs. 5%; P = 0.001), diagnosis of hypertension (71% vs. 39%; P = 0.013) and chronic kidney disease (24% vs. 4%; P = 0.008). The distributions of DOACs were: Number at risk DOAC Enoxaparin rivaroxaban, n = 11; apixaban, n = 5; dabigatran, n = 5. No patients initially treated with LMWH or a DOAC later switched anticoagulant classes. In patients with brain metastases, DOACs did not increase the incidence of any ICH relative to enoxaparin (12-month cumulative incidence 27.8% vs. 52.9%; P = 0.15) nor major ICH (12-month cumulative incidence 11.1% vs. 17.8%; P = 0.38), as shown in Fig. 2 . The median time from diagnosis of brain metastases to initiation of a DOAC or LMWH was statistically similar (9 and 12 months, respectively; Wilcoxon P = 0.55). Length of anticoagulation was not statistically different for DOAC and enoxaparin-treated patients (median duration 4 months vs. 3 months, respectively; P = 0.054). The median number of radiographic studies was similar in both LMWH and DOAC groups (9 and 8, respectively; P = 0.82). There were no deaths within 30 days of ICH in either the DOAC or LMWH cohort.
Discussion
Recent data from randomized clinical trials established the efficacy of DOACs for the treatment of cancer-associated thrombosis but with an increased risk of hemorrhage [7, 8] . Considering the risk of hemorrhage with DOACs in cancer cohorts, it is important to establish whether their use is specifically associated with an increased risk of intracranial hemorrhage compared with LMWH. In our retrospective cohort study, we did not observe an increased incidence of hemorrhage with the use of DOACs relative to LMWH in either patients with primary brain tumors or those with secondary brain metastases. In fact, we observed a significant reduction in the incidence of major hemorrhage with the use of DOACs in patients with primary brain tumors.
Patients with brain tumors were not excluded from entry into either of the recently reported randomized trials comparing rivaroxaban or edoxaban with dalteparin for the treatment of cancer-associated thrombosis [7, 8] . However, it is difficult to draw conclusions based on limited outcome-specific data provided in patients with brain tumors. In the Select-D cohort, there were only three patients enrolled with primary brain tumors with no reported hemorrhages and the number of patients with brain metastases was not reported [7] . In the Hokusai VTE Cancer study, two of 31 (6.5%) patients with brain tumors on edoxaban were diagnosed with a major hemorrhage compared with four of 43 (9.3%) receiving dalteparin (P = 1.0) [8] . No details were provided regarding the nature of the major hemorrhages and whether any were intracranial.
Strengths of this study include a blinded review of radiology images to minimize classification bias as well as strict criteria for ICH that include objective definition of major hemorrhage based on hemorrhage volume [11] . Implementing these criteria, we previously demonstrated the relative safety of LMWH in the treatment of VTE in patients with brain tumors [10] . The observed safety of DOACs compared with LMWH is unlikely to be a result of ascertainment bias considering the length of DOAC exposure tended to be longer than that for LMWH and a similar number of radiographic studies were performed in each group. Selection bias is a potential concern for the current study as treating clinicians determined who would be appropriate for a DOAC rather than LMWH. It is possible that patients with poorer performance status were selected for injections rather than oral anticoagulants and thus had a higher risk of hemorrhage. Reassuringly, we observed relative safety of DOACs despite an apparent imbalance in baseline hemorrhage risks in the DOAC group; those patients who received DOACs were also more likely to be taking aspirin, have underlying chronic kidney disease or be diagnosed with hypertension. A randomized clinical trial would be needed to definitively establish the relative benefit of DOACs over LMWH in patients with glioma. However, considering Number at risk DOAC Enoxaparin DOACs are efficacious in cancer patients and favored by patients because of their ease of administration, and in view of our safety data, we anticipate that it would be very difficult to recruit patients to such a trial.
Our group and others noted a significantly increased risk of ICH in patients with primary brain tumors treated with LMWH compared with no anticoagulation [3, 4] . Reassuringly, we did not observe any ICH among the 20 patients with primary brain tumors treated with DOACs, compared with an ICH rate of 18% at 1 year with LMWH. The lack of ICH with DOACs was especially notable considering median exposure was almost three times longer than that of LMWH. DOACs are known to have a lower risk of ICH compared with warfarin in noncancer cohorts, namely in patients with atrial fibrillation [12, 13] , but to the best of our knowledge, this study is the first to point to an improved safety profile in high-risk patients with primary brain tumors.
We conclude that DOACs have a favorable safety profile in patients with primary and metastatic brain tumors in terms of ICH risk and believe a DOAC is a reasonable option to treat venous thromboembolism in this population. 
